Multifaceted roles of cyclooxygenase-2 in lung cancer

Drug Resistance Updates

Volumn 7, Issue 3, 2004, Pages 169-184

  Riedl, Karen ^a   Krysan, Kostyantyn ^a   Põld, Mehis ^a   Dalwadi, Harnisha ^a   Heuze Vourc'h, Nathalie ^a   Dohadwala, Mariam ^a   Liu, Ming ^a   Cui, Xiaoyan ^a   Figlin, Robert ^a   Mao, Jenny T ^a   Strieter, Robert ^a   Sharma, Sherven ^a,b   Dubinett, Steven M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Celecoxib; Clinical trials; Cyclooxygenase; Lung cancer

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; ZILEUTON;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG TARGETING; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; ENZYMOLOGY; ESOPHAGITIS; GENE EXPRESSION; GENE FUNCTION; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NONHUMAN; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RASH; RESPIRATORY FAILURE; REVIEW; SEPSIS; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 3543050046     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2004.04.003     Document Type: Article

References (206)

1. Achiwa H., Yatabe Y., Hida T., Kuroishi T., Kozaki K., Nakamura S., Ogawa M., Sugiura T., Mitsudomi T., Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. 5:1999;1001-1005
2. Alaoui-Jamali M.A., Qiang H. The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery. Drug Resist. Update. 6:2003;95-107
3. Alleva D.G., Burger C.J., Elgert K.D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production: role of tumor-derived IL-10, TGF-beta and prostaglandin E2. J. Immunol. 153:1994;1674-1686
4. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., Carbone D.P., Gabrilovich D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6:2000;1755-1766
5. Altorki N.K., Keresztes R.S., Port J.L., Libby D.M., Korst R.J., Flieder D.B., Ferrara C.A., Yankelevitz D.F., Subbaramaiah K., Pasmantier M.W., Dannenberg A.J. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2645-2650
6. Amano H., Hayashi I., Endo H., Kitasato H., Yamashina S., Maruyama T., Kobayashi M., Satoh K., Narita M., Sugimoto Y., Murata T., Yoshimura H., Narumiya S., Majima M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197:2003;221-232
7. Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Khan M.A., Jones R.T., Harris C.C. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br. J. Cancer. 78:1998;233-239
8. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97:1996;2792-2802
9. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252
10. Bancroft, C.C., Chen, Z., Yeh, J., Sunwoo, J.B., Yeh, N.T., Jackson, S., Jackson, C., 2002. Effects of pharmacologic antagonists of epidermal growth factor receptor, P13K and MEK signal kinases on NF-kappa B and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int. J. Cancer 99, 538-548.
11. Bartolazzi A., Peach R., Aruffo A., Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med. 180:1994;53-66
12. Berg D., Zhang J., Lauricella D., Moore S. IL-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J. Immunol. 166:2001;2674-2680
13. Bianchi R., Grohmann U., Belladonna M., Silla S., Fallarino F., Ayroldi E., Fioretti M., Puccetti P. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol. 157:1996;1589-1597
14. Bissonnette M., Khare S., von Lintig F.C., Wali R.K., Nguyen L., Zhang Y., Hart J., Skarosi S., Varki N., Boss G.R., Brasitus T.A. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1. Cancer Res. 60:2000;4602-4609
15. Bouros D., Hatzakis K., Labrakis H., Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest. 121:2002;1278-1289
16. Brabender J., Park J., Metzger R., Schneider P.M., Lord R.V., Holscher A.H., Danenberg K.D., Danenberg P.V. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg. 235:2002;440-443
17. Buchanan F.G., Wang D., Bargiacchi F., DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 278:2003;35451-35457
18. Campa D., Zienolddiny S., Maggini V., Skaug V., Haugen A., Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 25:2004;229-235
19. Cao Y., Pearman A.T., Zimmerman G.A., McIntyre T.M., Prescott S.M. Intracellular unesterified arachidonic acid signals apoptosis. Proc. Natl. Acad. Sci. U.S.A. 97:2000;11280-11285
20. Carbone D., Choy H., Csiki I., Dang T., Campbell N., Garcia B., Morrow J., Saha D., Johnson D., Sandler A. Serum/plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in state III non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0059). Proc. Am. Soc. Clin. Oncol. 21:2002;1270
21. Cassidy P.B., Moos P.J., Kelly R.C., Fitzpatrick F.A. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin. Cancer Res. 8:2002;846-855
22. Catzavelos C., Tsao M.S., DeBoer G., Bhattacharya N., Shepherd F.A., Slingerland J.M. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 59:1999;684-688
23. Chambers A.F., Groom A.C., MacDonald I.C. Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer. 2:2002;563-572
24. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Shah J.P., Edelstein D., Soslow R.A., Koki A.T., Woerner B.M., Masferrer J.L., Dannenberg A.J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:1999;991-994
25. Chang H.C., Weng C.F. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol. Rep. 8:2001;1321-1325
26. Choy H., Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J. Natl. Cancer Inst. 95:2003;1440-1452
27. Coffey R.J., Hawkey C.J., Damstrup L., Graves-Deal R., Daniel V.C., Dempsey P.J., Chinery R., Kirkland S.C., DuBois R.N., Jetton T.L., Morrow J.D. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 94:1997;657-662
28. Colombo M., Vagliani M., Spreafico F., Parenza M., Chiodoni C., Melani C., Stoppacciaro A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 56:1996;2531-2534
29. Crew T.E., Elder D.J., Paraskeva C. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis. 21:2000;69-77
30. D'Amico T.A., Massey M., Herndon J.E. 2nd, Moore M.B., Harpole D.H. Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J. Thorac. Cardiovasc. Surg. 117:1999;736-743
31. D'Andrea A., Aste-Amezaga M., Valiante N., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1993;1041-1048
32. Daniel T.O., Liu H., Morrow J.D., Crews B.C., Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59:1999;4574-4577
33. Dannenberg A.J., Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 4:2003;431-436
34. Dannenberg A.J., Altorki N.K., Boyle J.O., Lin D.T., Subbaramaiah K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann. N.Y. Acad. Sci. 952:2001;109-115
35. Dazzi C., Cariello A., Maioli P., Solaini L., Scarpi E., Rosti G., Lanzanova G., Marangolo M. Prognostic and predictive value of intratumoral microvessel density in operable non-small-cell lung cancer. Lung Cancer. 24:1999;81-88
36. De Vita F., Orditura M., Galizia G., Romano C., Roscigno A., Lieto E., Catalano G. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest. 117:2000;365-373
37. Dohadwala M., Batra R.K., Luo J., Lin Y., Krysan K., Pold M., Sharma S., Dubinett S.M. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J. Biol. Chem. 277:2002;50828-50833
38. Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty G., Sharma S., Huang M., Pold M., Batra R., Dubinett S.M. Non-small cell lung cancer cylooxygenase-2- dependent invasion is mediated by CD44. J. Biol. Chem. 276:2001;20809-20812
39. Duarte I.G., Bufkin B.L., Pennington M.F., Gal A.A., Cohen C., Kosinski A.S., Mansour K.A., Miller J.I. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 115:1998;652-658. (discussion 658-659)
40. Dubinett S.M., Sharma S., Huang M., Dohadwala M., Pold M., Mao J.T. Cyclooxygenase-2 in lung cancer. Prog. Exp. Tumor Res. 37:2003;138-162
41. DuBois R., Shao J., Tsujii M., Sheng H., Beauchamp R. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 56:1996;733-737
42. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1063-1073
43. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: part I. J. Clin. Oncol. 20:2002a;2881-2894
44. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: part II. J. Clin. Oncol. 20:2002b;3016-3028
45. Elder D.J., Halton D.E., Hague A., Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 3:1997;1679-1683
46. Eling T.E., Thompson D.C., Foureman G.L., Curtis J.F., Huges M.F. Prostaglandin H synthase and xenobiotic oxidation. Ann. Rev. Pharmacol. Toxicol. 30:1990;1-45
47. Erickson B.A., Longo W.E., Panesar N., Mazuski J.E., Kaminski D.L. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J. Surg. Res. 81:1999;101-107
48. Ermert L., Dierkes C., Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin. Cancer Res. 9:2003;1604-1610
49. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:1997;3381-3385
50. Ferreira C.G., Epping M., Kruyt F.A., Giaccone G. Apoptosis: target of cancer therapy. Clin. Cancer Res. 8:2002;2024-2034
51. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31
52. Folkman J. Angiogenesis-dependent diseases. Semin. Oncol. 28:2001;536-542
53. Fong K.M., Sekido Y., Minna J.D. Molecular pathogenesis of lung cancer. J. Thorac. Cardiovasc. Surg. 118:1999;1136-1152
54. Fontanini G., Bigini D., Vignati S., Basolo F., Mussi A., Lucchi M., Chine S., Angeletti C.A., Harris A.L., Bevilacqua G. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J. Pathol. 177:1995;57-63
55. Frantz B., O'Neill E.A. The effect of sodium salicylate and aspirin on NF-kappa B. Science. 270:1995;2017-2019
56. Fujita M., Fukui H., Kusaka T., Morita K., Fujii S., Ueda Y., Chiba T., Sakamoto C., Kawamata H., Fujimori T. Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J. Gastroenterol. Hepatol. 15:2000;1277-1281
57. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 19:2000;19-27
58. Giatromanolaki A., Koukourakis M., O'Byrne K., Fox S., Whitehouse R., Talbot D.C., Harris A.L., Gatter K.C. Prognostic value of angiogenesis in operable non-small cell lung cancer. J. Pathol. 179:1996;80-88
59. Gilhooly E., Rose D. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int. J. Oncol. 15:1999;267-270
60. Grosch S., Tegeder I., Niederberger E., Brautigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15:2001;2742-2744
61. Guddo F., Fontanini G., Reina C., Vignola A.M., Angeletti A., Bonsignore G. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum. Pathol. 30:1999;788-794
62. Hagenbaugh A., Sharma S., Dubinett S., Wei S.H., Aranda R., Cheroutre H., Fowell D.J., Binder S., Tsao B., Locksley R.M., Moore K.W., Kronenberg M. Altered immune responses in IL-10 transgenic mice. J. Exp. Med. 185:1997;2101-2110
63. Halak B.K., Maguire H.C. Jr., Lattime E.C. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 59:1999;911-917
64. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
65. Handel-Fernandez M.E., Ching X., Herbert L.M., Lopez D.M. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-g production in mammary tumor-bearing mice. J. Immunol. 158:1997;280-286
66. Hara A., Yoshimi N., Niwa M., Ino N., Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res. 88:1997;600-604
67. Harizi H., Juzan M., Pitard V., Moreau J.F., Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J. Immunol. 168:2002;2255-2263
68. Harpole D.H. Jr., Richards W.G., Herndon J.E. II, Sugarbaker D.J. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann. Thorac. Surg. 61:1996;1470-1476
69. Hasturk S., Kemp B., Kalapurakal S.K., Kurie J.M., Hong W.K., Lee J.S. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer. 94:2002;1023-1031
70. Hatanaka H., Abe Y., Kamiya T., Morino F., Nagata J., Tokunaga T., Oshika Y., Suemizu H., Kijima H., Tsuchida T., Yamazaki H., Inoue H., Nakamura M., Ueyama Y. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann. Oncol. 11:2000;815-819
71. Hatanaka H., Abe Y., Naruke M., Tokunaga T., Oshika Y., Kawakami T., Osada H., Nagata J., Kamochi J., Tsuchida T., Kijima H., Yamazaki H., Inoue H., Ueyama Y., Nakamura M. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin. Cancer Res. 7:2001;1287-1292
72. Hawk E.T., Viner J.L., Dannenberg A., DuBois R.N. COX-2 in cancer - a player that's defining the rules. J. Natl. Cancer Inst. 94:2002;545-546
73. He T.C., Chan T.A., Vogelstein B., Kinzler K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 99:1999;335-345
74. Heasley L., Thaler S., Nicks M., Price B., Skorecki K., Nemenoff R.A. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem. 272:1997;14501-14504
75. Hennekens C.H., Buring J.E., Manson J.E., Stampfer M., Rosner B., Cook N.R., Belanger C., LaMotte F., Gaziano J.M., Ridker P.M., Willett W., Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:1996;1145-1149
76. Herschman H. Review: prostaglandin synthase 2. Biochim. Biophys. Acta. 1299:1996;125-140
77. Heuze-Vourc'h N., Zhu L., Krysan K., Batra R.K., Sharma S., Dubinett S.M. Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res. 63:2003;766-770
78. Hida T., Kozaki K., Ito H., Miyaishi O., Tatematsu Y., Suzuki T., Matsuo K., Sugiura T., Ogawa M., Takahashi T. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin. Cancer Res. 8:2002;2443-2447
79. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., Sugiura T., Ogawa M., Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6:2000;2006-2011
80. Hida T., Leyton J., Makheja A., Ben-Av P., Hla T., Martinez A., Mulshine J., Malkani S., Chung P., Moody T. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 18:1998a;775-782
81. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cycloxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:1998b;3761-3764
82. Hillerdal G., Henderson D.W. Asbestos, asbestosis, pleural plaques and lung cancer. Scand. J. Work Environ. Health. 23:1997;93-103
83. Hirsch F., Franklin W., Gazdar A., Bunn P. Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 7:2001;5-22
84. Hirsch F.R., Franklin W.A., Bunn P.A. Jr. Expression of target molecules in lung cancer: challenge for a new treatment paradigm. Semin. Oncol. 29:2002;2-8
85. Ho I., Lee T. Arsenite pretreatment attenuates benzo[a]pyrene cytotoxicity in a human lung adenocarcinoma cell line by decreasing cyclooxygenase-2 levels. J. Toxicol. Environ. Health A. 65:2002;245-263
86. Hosomi Y., Yokose T., Hirose Y., Nakajima R., Nagai K., Nishiwaki Y., Ochiai A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 30:2000;73-81
87. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275:2000;11397-11403
88. Hsueh C.T., Chiu C.F., Kelsen D.P., Schwartz G.K. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother. Pharmacol. 45:2000;389-396
89. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965
90. Huang M., Wang J., Lee P., Sharma S., Mao J.T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S.M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 55:1995;3847-3853
91. Huang C., Ma W.Y., Hanenberger D., Cleary M.P., Bowden G.T., Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J. Biol. Chem. 272:1997;26325-26331
92. Huang M., Sharma S., Mao J.T., Dubinett S.M. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol. 157:1996;5512-5520
93. Huang M., Stolina M., Sharma S., Mao J., Zhu L., Miller P., Wollman J., Herschman H., Dubinett S.M. Non-small cell lung cancer cyclooxygenase-2- dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58:1998;1208-1216
94. Hung W.C., Chang H.C., Pan M.R., Lee T.H., Chuang L.Y. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol. Pharmacol. 58:2000;1398-1403
95. Hwang D.H., Fung V., Dannenberg A.J. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia. 4:2002;91-97
96. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics. CA Cancer J. Clin. 53:2003;5-26
97. Johnson D., Csiki I., Gonzalez A., Carbone D., Gautam S., Campbell N., Morrow J., Sandler A. Cyclooxygenase-2 (COX-2) inhibition in non-small cell lung cancer (NSCLC): preliminary results of a phase II trial. Proc. Am. Soc. Clin. Oncol. 22:2003;640. (abstract 2575)
98. 2, promote Th2 responses. Adv. Exp. Med. Biol. 417:1997;363-367
99. Kelley D., Subbaramaiah K., Sacks P., Schantz S., Tanabe T., Inoue H., Ramonetti J., Dannenberg A. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 18:1997;795-799
100. Khuri F., Wu H., Lee J., Kemp B., Lotan R., Lippman S., Feng L., Hong W., Xu X.-C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7:2001;861-867
101. Kim G.E., Kim Y.B., Cho N.H., Chung H.C., Pyo H.R., Lee J.D., Park T.K., Koom W.S., Chun M., Suh C.O. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin. Cancer Res. 10:2004;1366-1374
102. Kim H.S., Youm H.R., Lee J.S., Min K.W., Chung J.H., Park C.S. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer. 42:2003;163-170
103. Kim J., Modlin R.L., Moy R.L., Dubinett S.M., McHugh T., Nickoloff B.J., Uyemura K. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol. 155:1995;2240-2247
104. Kinoshita T., Takahashi Y., Sakashita T., Inoue H., Tanabe T., Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim. Biophys. Acta. 1438:1999;120-130
105. Kinzler K.W., Vogelstein B. Landscaping the cancer terrain. Science. 280:1998;1036-1037
106. Kishi K., Petersen S., Petersen C., Hunter N., Mason K., Masferrer J.L., Tofilon P.J., Milas L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;1326-1331
107. Koki A.T., Leahy K.M., Masferrer J.L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs. 8:1999;1623-1638
108. Komaki R., Liao Z., Milas L. Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin. Oncol. 31:2004;47-53
109. Konishi T., Huang C.L., Adachi M., Taki T., Inufusa H., Kodama K., Kohno N., Miyake M. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int. J. Oncol. 16:2000;501-511
110. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Comley M., Whitehouse R.M., Talbot D.C., Gatter K.C., Harris A.L. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br. J. Cancer. 75:1997;477-481
111. Kozaki K., Koshikawa K., Tatematsu Y., Miyaishi O., Saito H., Hida T., Osada H., Takahashi T. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene. 20:2001;4228-4234
112. Krysan K., Merchant F.H., Zhu L., Dohadwala M., Luo J., Lin Y., Heuze-Vourc'h N., Pold M., Seligson D., Chia D., Goodglick L., Wang H., Strieter R., Sharma S., Dubinett S. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 18:2004a;206-208
113. 2 activates MAPk/Erk pathway in non-small cell lung cancer cells in an EGF receptor-independent manner. Proc. Am. Assoc. Cancer Res. 45:2004b;907. (abstract 3934)
114. Lamb R.F., Hennigan R.F., Turnbull K., Katsanakis K.D., MacKenzie E.D., Birnie G.D., Ozanne B.W. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol. Cell Biol. 17:1997;963-976
115. Leahy K., Koki A., Masferrer J. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem. 7:2000;1163-1170
116. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., Masferrer J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:2002;625-631
117. Liao Z., Chen Y., Komaki R., Cox J., Milas L. A phase I study combining thoracic radiation (RT) with celecoxib in patients with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 22:2003;216. (abstract 867)
118. Lin M.T., Lee R.C., Yang P.C., Ho F.M., Kuo M.L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 276:2001;48997-49002
119. Lippman S.M., Lee J.J., Karp D.D., Vokes E.E., Benner S.E., Goodman G.E., Khuri F.R., Marks R., Winn R.J., Fry W., Graziano S.L., Gandara D.R., Okawara G., Woodhouse C.L., Williams B., Perez C., Kim H.W., Lotan R., Roth J.A., Hong W.K. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 93:2001;605-618
120. Liu X.H., Kirschenbaum A., Yao S., Lee R., Holland J.F., Levine A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164:2000;820-825
121. Liu X.H., Yao S., Kirschenbaum A., Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58:1998;4245-4249
122. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., Angeletti C.A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 340:1992;145-146
123. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer. 1:2001;222-231
124. Mao J.T., Roth M.D., Serio K.J., Baratelli F., Zhu L., Holmes E.C., Strieter R.M., Dubinett S.M. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin. Cancer Res. 9:2003;5835-5841
125. Marrogi A.J., Travis W.D., Welsh J.A., Khan M.A., Rahim H., Tazelaar H., Pairolero P., Trastek V., Jett J., Caporaso N.E., Liotta L.A., Harris C.C. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin. Cancer Res. 6:2000;4739-4744
126. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311
127. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Oncol. 11:2001;290-299
128. Milas L., Furuta Y., Hunter N., Nishiguchi I., Runkel S. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res. 50:1990;4473-4477
129. Milas L., Hunter N., Furuta Y., Nishiguchi I., Runkel S. Antitumour effects of indomethacin alone and in combination with radiotherapy: role of inhibition of tumour angiogenesis. Int. J. Radiat. Biol. 60:1991;65-70
130. Milas L., Kishi K., Hunter N., Mason K., Masferrer J.L., Tofilon P.J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 91:1999;1501-1504
131. Molina-Holgado E., Arevalo-Martin A., Ortiz S., Vela J.M., Guaza C. Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10. Neurosci. Lett. 324:2002;237-241
132. Moore K.W., de Waal-Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:2001;683-765
133. Moos P.J., Muskardin D.T., Fitzpatrick F.A. Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme. J. Immunol. 162:1999;467-473
134. Murata H., Kawano S., Tsuji S., Tsuji M., Sawaoka H., Kimura Y., Shiozaki H., Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am. J. Gastroenterol. 94:1999;451-455
135. Naruke M., Abe Y., Hatanaka H., Ohnishi Y., Yamazaki H., Kijima H., Nakamura M., Ueyama Y., Kobayashi K. Interleukin-10 expression is correlated with growth fraction in human non-small cell lung cancer xenografts. Int. J. Oncol. 18:2001;1213-1217
136. Neuner A., Schindel M., Wildenberg U., Muley T., Lahm H., Fischer J.R. Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer. 34:2001;579-582
137. Niki T., Kohno T., Iba S., Moriya Y., Takahashi Y., Saito M., Maeshima A., Yamada T., Matsuno Y., Fukayama M., Yokota J., Hirohashi S. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am. J. Pathol. 160:2002;1129-1141
138. Ochiai M., Oguri T., Isobe T., Ishioka S., Yamakido M. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn. J. Cancer Res. 90:1999;1338-1343
139. Ohta Y., Shridhar V., Bright R.K., Kalemkerian G.P., Du W., Carbone M., Watanabe Y., Pass H.I. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer. 81:1999;54-61
140. Omenn, G., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A., Keogh, J.P., Meyskens, F.L, Valanis, B., Williams, J.H., Barnhart, S., Hammar, S., 1996. Effects of a combination of beta carotene and Vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med, 1150-1155.
141. Ono Y., Nakanishi Y., Gotoh M., Sakamoto M., Hirohashi S. Epidermal growth factor receptor gene amplification is correlated with laminin-5 gamma2 chain expression in oral squamous cell carcinoma cell lines. Cancer Lett. 175:2002;197-204
142. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8:2002;289-293
143. Pan M.R., Chuang L.Y., Hung W.C. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett. 508:2001;365-368
144. Petersen C., Petersen S., Milas L., Lang F.F., Tofilon P.J. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin. Cancer Res. 6:2000;2513-2520
145. Pisters K.M., Ginsberg R.J., Giroux D.J., Putnam J.B. Jr., Kris M.G., Johnson D.H., Roberts J.R., Mault J., Crowley J.J., Bunn P.A. Jr. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality lung oncology team. J. Thorac. Cardiovasc. Surg. 119:2000;429-439
146. Pold M., Dohadwala M., Luo J., Lin Y., Dubinett S.M. Microarray identifies cyclooxygenase-2-dependent modulation of insulin-like growth factor binding protein-3 in non-small cell lung cancer cells. Chest. 121:2002;29S-30S
147. Pold M., Zhu L., Sharma S., Burdick M.D., Lin Y., Lee P.P., Pold A., Luo J., Krysan K., Dohadwala M., Mao J.T., Batra R.K., Strieter R.M., Dubinett S.M. Cyclooxygenase-2 dependent expression of angiogenic CXC chemokine, ENA-78/CXC5 and IL-8/CXCL8, in human NSCLC. Cancer Res. 64:2004;1853-1860
148. Pomini F., Caruso A., Challis J.R. Interleukin-10 modifies the effects of
149. Pyke C., Romer J., Kallunki P., Lund L.R., Ralfkiaer E., Dano K., Tryggvason K. The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am. J. Pathol. 145:1994;782-791
150. Pyke C., Salo S., Ralfkiaer E., Romer J., Dano K., Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res. 55:1995;4132-4139
151. Pyo, H., Choy, H., Amorino, G.P., Kim, J.P., Cao, Q., Hercules, S.K., DuBois, R.N., 2001. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res. 7, 2998-3005.
152. Qin L., Yaohong D., Pahud D., Robson N., Shaked A., Bromberg J. Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum. Gene Ther. 8:1997;1365-1374
153. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:2000;34-44
154. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 58:1998;5354-5360
155. Roth M.D., Golub S.H. Human pulmonary macrophages utilize prostaglandins and transforming growth factor beta1 to suppress lymphocyte activation. J. Leukoc. Biol. 53:1993;366-371
156. Sanchez-Alcazar J.A., Bradbury D.A., Pang L., Knox A.J. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer. 40:2003;33-44
157. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E.S., Takei Y., Nagano K., Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 274:1998;G1061-G1067
158. Schreinemachers D.M., Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 5:1994;138-146
159. Seiter S., Arch R., Reber S., Komitowski D., Hofmann M., Ponta H., Herrlich P., Matzku S., Zoller M. Prevention of tumor metastasis formation by anti-variant CD44. J. Exp. Med. 177:1993;443-455
160. Shah T., Ryu S., Lee H.J., Brown S., Kim J.H. Pronounced radiosensitization of cultured human cancer cells by COX inhibitor under acidic microenvironment. Int. J. Radiat. Oncol. Biol. Phys. 53:2002;1314-1318
161. Shamma A., Yamamoto H., Doki Y., Okami J., Kondo M., Fujiwara Y., Yano M., Inoue M., Matsuura N., Shiozaki H., Monden M. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res. 6:2000;1229-1238
162. Shankavaram U.T., Lai W.C., Netzel-Arnett S., Mangan P.R., Ardans J.A., Caterina N., Stetler-Stevenson W.G., Birkedal-Hansen H., Wahl L.M. Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J. Biol. Chem. 276:2001;19027-19032
163. Sharma S., Stolina M., Lin Y., Gardner B., Miller P.W., Kronenberg M., Dubinett S.M. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 163:1999;5020-5028
164. Sharma S., Stolina M., Yang S.C., Baratelli F., Lin J.F., Atianzar K., Luo J., Zhu L., Lin Y., Huang M., Dohadwala M., Batra R.K., Dubinett S.M. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 9:2003;961-968
165. Sheng H., Shao J., Dixon D.A., Williams C.S., Prescott S.M., DuBois R.N., Beauchamp R.D. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. 275:2000;6628-6635
166. 2 in human colon cancer cells. Cancer Res. 58:1998;362-366
167. Shiff S.J., Qiao L., Tsai L.L., Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96:1995;491-503
168. Shirane M., Harumiya Y., Ishida N., Hirai A., Miyamoto C., Hatakeyama S., Nakayama K., Kitagawa M. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 274:1999;13886-13893
169. Skyldberg B., Salo S., Eriksson E., Aspenblad U., Moberger B., Tryggvason K., Auer G. Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl. Cancer Inst. 91:1999;1882-1887
170. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69:2000;145-182
171. Sombroek C.C., Stam A.G., Masterson A.J., et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168:2002;4333-4343
172. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., Chen C.S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94:2002;585-591
173. Sordat I., Bosman F.T., Dorta G., Rousselle P., Aberdam D., Blum A.L., Sordat B. Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J. Pathol. 185:1998;44-52
174. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., Koki A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 89:2000;2637-2645
175. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7:2001;186-191
176. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., Zhu L., Kronenberg M., Miller P.W., Portanova J., Lee J.C., Dubinett S.M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164:2000;361-370
177. Su J.L., Shih J.Y., Yen M.L., Jeng Y.M., Chang C.C., Hsieh C.Y., Wei L.H., Yang P.C., Kuo M.L. Cyclooxygenase-2 induces EP(1)- and HER-2/Neu-dependent vascular endothelial growth factor-C upregulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 64:2004;554-564
178. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampart A., Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274:1999;10911-10915
179. Subbaramaiah K., Hart J.C., Norton L., Dannenberg A.J. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J. Biol. Chem. 275:2000;14838-14845
180. Subbaramaiah K., Marmo T.P., Dixon D.A., Dannenberg A.J. Regulation of cyclooxygenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J. Biol. Chem. 278:2003;37637-37647
181. Subbaramaiah K., Telang N., Ramonetti J.T., Araki R., DeVito B., Weksler B.B., Dannenberg A.J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56:1996;4424-4429
182. Swisher S., Kiertscher S., Golub S., Holmes E., Roth M. Pulmonary macrophages suppress the proliferation and cytotoxicity of tumor-infiltrating lymphocytes. Am. J. Resp. Cell Mol. Biol. 8:1993;486-492
183. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94:2002;252-266
184. Tsujii M., Dubois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell. 83:1995;493-501
185. Tsujii M., Kawano S., DuBois R. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3336-3340
186. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716
187. Uefuji K., Ichikura T., Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin. Cancer Res. 6:2000;135-138
188. Urosevic M., Kurrer M.O., Kamarashev J., Mueller B., Weder W., Guenter B., Stahel R.A., Dummer R., Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 159:2001;817-824
189. Wardlaw S.A., March T.H., Belinsky S.A. Cyclooxygenase-2 expression in abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions. Carcinogenesis. 21:2000;1371-1377
190. Wardlaw S.A., Zhang N., Belinsky S.A. Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/Enhancer-binding protein and activating transcription factor/cAMP response element-binding protein. Mol. Pharmacol. 62:2002;326-333
191. Watkins D.N., Lenzo J.C., Segal A., Garlepp M.J., Thompson P.J. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur. Respir. J. 14:1999;412-418
192. West K.A., Castillo S.S., Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Update. 5:2002a;234-248
193. West H., Yaziji H., Giarrita S., Livingston R., Vallieres E., Wood D., Gown A. Cyclooxygenase-2 (COX-2) overexpression by immunohistochemistry (IHC) is associated with more aggressive biologic behavior of non-small cell lung cancer (NSCLC) tumors. Proc. Am. Soc. Clin. Oncol. 21:2002b;1235
194. Wick M., Hurteau G., Dessev C., Chan D., Geraci M.W., Winn R.A., Heasley L.E., Nemenoff R.A. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol. Pharmacol. 62:2002;1207-1214
195. Wiese F., Thompson P., Kadlubar F. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis. 22:2001;5-10
196. Wikstrom P., Stattin P., Franck-Lissbrant I., Damber J.E., Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate. 37:1998;19-29
197. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:2000;1589-1594
198. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001
199. Wu, C.-Y., Demeure, C., Kiniwa, M., Gately, M., Delespesse, G., 1993. IL-12 induces the production of IFN-g by neonatal human CD4 T cells. J. Immunol. 151, 1938-1949.
200. Xu X.C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs. 13:2002;127-137
201. Yang L., Yamagata N., Yadav R., Brandon S., Courtney R.L., Morrow J.D., Shyr Y., Boothby M., Joyce S., Carbone D.P., Breyer R.M. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111:2003;727-735
202. Yao R., Rioux N., Castonguay A., You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp. Lung Res. 26:2000;731-742
203. KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res. 58:1998;1042-1047
204. Yip-Schneider M.T., Barnard D.S., Billings S.D., Cheng L., Heilman D.K., Lin A., Marshall S.J., Crowell P.L., Marshall M.S., Sweeney C.J. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 21:2000;139-146
205. Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13:1999;35-48
206. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14:2000;163-176